Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lazolex is a topical emollient gel medical device based on an extract of Juglans regia (walnut) formulated in a matrix of three different silicones to create a mechanical barrier on the skin and mucosa, providing a moist, protective environment that relieves itching, stinging, burning, and dryness in inflammatory skin diseases such as dermatitis and herpes simplex–associated mucocutaneous lesions.[1][4][6][13] Developed in Georgia and manufactured by Hartington Pharmaceutical, Lazolex has been clinically evaluated as a 5–10% walnut pericarp extract gel applied several times daily for 10 days, demonstrating rapid symptom relief, accelerated healing of HSV-1 and HSV-2 lesions, and reduced recurrence rates, effects attributed to barrier restoration, local anti-inflammatory and antiviral activity, and immunomodulatory properties of the walnut extract.[1][3][5][8][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lazolex.